Want to join the conversation?
$EW now sees 2016 sales to be at high end of its prior $2.7-3Bil range based on strong 1H results, expected 3Q approval of intermediate risk in the U.S., and momentum of therapy adoption globally. $EW raised FY16 adjusted EPS outlook to $2.78-2.88 from prior range of $2.67-2.77. For 3Q16, $EW sees sales of $720-760MM and adjusted EPS of $0.62-0.68.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?